Application
Human SkinApplication
WB Suggested Anti-TAF9 Antibody Titration: 0.125ug/mlELISA Titer: 1:312500Positive Control: Human Small IntestineApplication
Quiescent human colon carcinoma HCT116 cultures were treated with 10% FBS for three time points (0, 15, 30min) or (0, 30, 60min) were used in Matrix-ChIP and real-time PCR assays at EGR1 gene (Exon1) and 15kb upstream site.| Product Name | Rabbit anti-TAF9 polyclonal antibody - N-terminal region |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | AK6, CIP, CINAP, TAF2G, AD-004, hCINAP, CGI-137, TAFII31, TAFII32, MGC:1603, MGC:3647, MGC:5067, TAFIID32 |
| Immunogen | The immunogen for anti-TAF9 antibody: synthetic peptide directed towards the N terminal of human TAF9 |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:500~1:2000 IHC:1:50~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Gene Symbol | TAF9 |
|---|---|
| Gene Synonyms | TAF9 |
| Gene Full Name | TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa |
| Gene Summary | Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes one of the smaller subunits of TFIID that binds to the basal transcription factor GTF2B as well as to several transcriptional activators such as p53 and VP16. |
| Alternative Names | AK6 CIP CINAP TAF2G AD-004 hCINAP CGI-137 TAFII31 TAFII32 MGC:1603 MGC:3647 MGC:5067 TAFIID32 |
| Molecular Weight(MW) | 19kDa |
| Sequence | 169 amino acids |
| Entrez Gene | 6880 |
|---|---|
| SwissProt ID | Q9Y3D8 |
| Protein Accession | NP_001015891 |
Application
Human Skin
Application
WB Suggested Anti-TAF9 Antibody Titration: 0.125ug/mlELISA Titer: 1:312500Positive Control: Human Small Intestine
Application
Quiescent human colon carcinoma HCT116 cultures were treated with 10% FBS for three time points (0, 15, 30min) or (0, 30, 60min) were used in Matrix-ChIP and real-time PCR assays at EGR1 gene (Exon1) and 15kb upstream site.| Application Notes | WB:1:500~1:2000 IHC:1:50~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Aliquot and store at -20°C. Avoid repeated freeze / thaw cycles |
| Storage Buffer | phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
